Roche
Boehringer submits new lung cancer drug
September 20, 2012Research and Development, Sales and Marketing Boehringer, NSCLC, Roche, Tarceva, afatinib
Boehringer Ingelheim has filed its new lung cancer drug with the EMA. Afatinib is the latest targeted therapy for lung …
Roche winning on Perjeta supply, but running short of Boniva
August 20, 2012Manufacturing and Production, Sales and Marketing Boniva, Perjeta, Roche, breast cancer
Roche is getting production for its new breast cancer drug Perjeta back on track after some initial teething troubles, but …
Novartis eye drug succeeds in Phase III trial
August 16, 2012Sales and Marketing FDA, Novartis, Ocriplasmin, Roche, VMA
Novartis has posted positive results for its investigational eye drug ocriplasmin. The Phase III study found that ocriplasmin significantly resolved …
New Avastin data could be bad news for Lucentis
August 14, 2012Research and Development, Sales and Marketing DMO, Lucentis, Novartis, Roche, avastin, off label, off-label, wet AMD
The day after Novartis gained a new US licence for Lucentis to treat diabetic macular oedema, new data was published …
Roche posts strong sales results
July 27, 2012Sales and Marketing Pegasys, Perjeta, Roche, Zelboraf, dalcetrapib
Roche has published healthy revenue growth for the first half of 2012, but its profits have taken a hit. The …
Lucentis price cut ends PCT-Novartis dispute
July 26, 2012Sales and Marketing ABPI, NHS, PCTs, Roche, SHIP Cluster, avastin
An NHS body has been persuaded to reverse its policy of recommending Avastin for wet AMD. The Southampton, Hampshire, Isle …
Erbitux fails in gastric cancer trial
July 6, 2012Research and Development, Sales and Marketing Erbitux, Merck Serono, Roche, failure, gastric cancer
Merck’s Erbitux has failed to increase survival in patients with gastric cancer, representing a blow to the firm’s ambition to …
NICE no for Avastin in breast cancer
July 6, 2012Sales and Marketing NICE, Roche, avastin, breast cancer, rejection
NICE has decided once again not to recommend Roche’s Avastin on the NHS for the first line treatment of metastatic …
FDA clears Arena and Eisai’s obesity drug
June 28, 2012Sales and Marketing Arena, Belviq, Eisai, FDA, Qnexa, Roche, obesity
Eisai and Arena’s Belviq has gained FDA approval, making it the first obesity drug to be approved in over ten …
NICE final yes for Zytiga and Tarceva
June 27, 2012Sales and Marketing Janssen, NHS, NICE, NSCLC, Roche, Tarceva, Zytiga
In final guidance published today, NICE is recommending two new drugs for patients with prostate and lung cancer. Janssen’s Zytiga …
Roche cuts 1,000 R&D jobs
June 27, 2012Research and Development, Sales and Marketing AZ, Genentech, Novartis, R&D, Roche, cuts
Roche will make major cuts to its research operations in the US and revamp operations in Europe. Roche will close …
Roche’s Perjeta increases survival
June 27, 2012Research and Development, Sales and Marketing EMA, FDA, Herceptin, Perjeta, Roche, breast cancer
Roche’s new drug Perjeta has scored another trial success by increasing overall survival in certain breast cancer patients. The new …
Roche earmarks $300m for diagnostics HQ
June 26, 2012Manufacturing and Production Diagnostics, Illumina, Roche, US, manufacturing
Roche has said it intends to invest $300 million over the next 10 years at its diagnostics headquarters in Indianapolis, …
Roche failed to investigate 80,000 safety incidents
June 25, 2012Manufacturing and Production, Sales and Marketing EMA, MHRA, Roche, pharmacovigilance
The European Medicines Agency is investigating Roche after ‘deficiencies’ in the manufacturer’s pharmacovigilance processes came to light. It has emerged …
Roche signs research deal on autism spectrum disorders
June 19, 2012Research and Development, Sales and Marketing ASD, FXS, Roche, Seaside Therapeutics, asperger's, autism
Roche has signed an agreement with Seaside Therapeutics to develop new treatments for autism and other neurodevelopmental conditions such as …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
